Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cerdelga and Cerezyme Combination in Type III Gaucher Disease
NCT03519646Completed
- Sponsor
- National Taiwan University Hospital
- Start
- Apr 2018
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of eliglustat in Gaucher disease type 3, sponsored by National Taiwan University Hospital. Primary endpoint: Adverse Events at 24 months. Started Apr 2018; status: completed.
02
Drugs
eliglustat
03
Conditions
Gaucher disease type 3
Beyond the preview
Go deeper on NCT03519646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03519646.